According to FutureWise analysis, the market for aspiration and biopsy needles is expected to reach US$ 1.63 billion by 2033, growing at a CAGR of 6.7%.
The global market is predicted to witness a surge as there is a rise in the occurrences of cancer, favorable sanctions by global health and government organizations along with a greater tendency to opt for diagnostic procedures which are minimally invasive. Biopsy performed on the breast involves the removal of tissues and cells in certain areas of the breast that are vulnerable to diseases such as cancer. These tissues and cells are examined under a microscope to identify potential chances of cancer. When a hollow needle is inserted for the purpose of removing tissue samples from the breast, then it is called a core needle biopsy. Core needle biopsy is carried out for the detection of any lump or mass or any other suspicious spots which is identified after imaging testing or mammogram. In the case of biopsy that entails fine needles, there is also a removal of cells potentially cancerous lumps in the breast.
The needle that is used for performing the fine needle biopsy happens to be thinner in comparison to the needle used in the biopsy of the core needle. There are different kinds of biopsies which includes vacuum-assisted biopsy, core needle biopsy, shave biopsy, image guided biopsy, punch biopsy, excisional biopsy, incisional biopsy, fine needle aspiration, endoscopic biopsy, bone marrow biopsy and bone marrow aspiration. Two primary types of biopsies are surgical biopsy and needle biopsy. Surgical biopsy entails an incision to gather tissue samples and core needle biopsy is carried out in either hospitals and imaging centers. This biopsy is an image guided process. There are many benefits associated with such biopsies as the possibilities of sustaining an infection or a bruise are less. In case the lump is shown to be benign, then surgical biopsy will not be required. Although, there is a risk that the needle may not detect the tumor cells and as a result, one could misconstrue this as a non-cancerous cell.
Going by the segmentation of product, the market has been bifurcated into aspiration and biopsy needles. The segment for biopsy needles is anticipated to thrive at a very high CAGR during the forecast time frame because of the high presence of cancer and initiatives undertaken by certain healthcare facilities.
With end users, the market is fragmented into academic institutes, hospitals, research laboratories, imaging and diagnostic centers. The segment for hospital is projected to grow, in part, because of the developing healthcare framework in emerging nations, which shall inflate the aspiration and biopsy needles market size.